Proportion of mutations found according to gender and histological type of non-small-cell lung carcinoma (NSCLC)
| Gender | Histology | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | Female | Male | Adeno | Squamos | Large cell | Sarcomatoid | Adenosquamous | NOS | |
| Total | 552 | 200 (36.2%) | 352 (63.8%) | 254 (46.0%) | 186 (33.7%) | 79 (14.3%) | 7 (1.3%) | 5 (0.9%) | 21 (3.8%) |
| EGFR positive | 27 (4.9%) | 17 (8.5%) | 10 (2.8%) | 22 (8.7%) | 2 (1.1%) | 2 (2.5%) | 0 (0%) | 1 (20%) | 0 (0%) |
| EGFR negative | 525 | 183 (91.5%) | 342 (97.2%) | 232 (91.3%) | 184 (98.9%) | 77 (97.5%) | 7 (100%) | 4 (80%) | 21 (100%) |
| KRAS positive | 85 (15.4%) | 42 (21.0%) | 43 (12.2%) | 67 (26.4%) | 5 (2.7%) | 11 (13.9%E) | 0 (0%) | 0 (0%) | 2 (9.5%) |
| KRAS negative. | 467 | 158 (79.0%) | 309 (87.8%) | 187 (73.6%) | 181 (97.3%) | 68 (86.1%) | 7 (100%) | 5 (100%) | 19 (90.5%) |
No double mutations were found in this cohort.
Bold is used to highlight the most important findings with regard to the values published in the literature.
EGFR, epidermal growth factor receptor; NOS, non other specified.